Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review.

Cancers (Basel) · 2020 · PMC7563381 · PMID 32957736

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

ALK-positive patients showed a trend toward improved median PFS when receiving bevacizumab as part of either the pemetrexed–platinum combination or maintenance therapy (9.5 versus 5.5 months without bevacizumab; p = 0.087).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.